KYONGBO PHARMACEUTICAL CO., LTD. Logo

KYONGBO PHARMACEUTICAL CO., LTD.

Manufactures APIs and finished drugs, offering global CDMO services from development to production.

214390 | KO

Overview

Corporate Details

ISIN(s):
KR7214390007
LEI:
Country:
South Korea
Address:
충청남도 아산시 실옥로 174, 아산시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kyongbo Pharmaceutical Co., Ltd., established in 1987, is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company's portfolio includes general APIs, sterile APIs for cephalosporin and carbapenem injectables, and high-potency APIs for anticancer treatments. It also manufactures finished dosage forms, including solid oral drugs and sterile injectables. In addition to its own product lines, Kyongbo operates as a Contract Development and Manufacturing Organization (CDMO), providing integrated services from early-stage development through commercial cGMP production for a global client base. The company leverages its extensive experience and dedicated research facilities to innovate within the pharma-chemical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 50.4 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 115.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1021.1 KB
2025-07-31 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.0 KB
2025-07-25 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-09 00:00
Legal Proceedings Report
[기재정정]주요사항보고서(영업정지)
Korean 13.0 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-07-02 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 34.7 KB
2025-07-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 108.5 KB
2025-06-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-06-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-06-18 00:00
Legal Proceedings Report
[기재정정]주요사항보고서(영업정지)
Korean 13.4 KB
2025-06-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-06-17 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 35.5 KB

Automate Your Workflow. Get a real-time feed of all KYONGBO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYONGBO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYONGBO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America
ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America
ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America
ALMS
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America
ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.
United States of America
AMRN
AMGEN INC Logo
Biotech pioneer developing innovative human therapeutics for the world's toughest diseases.
United States of America
AMGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.